

One Hundred Thirteenth Congress  
of the  
United States of America

AT THE SECOND SESSION

*Begun and held at the City of Washington on Friday,  
the third day of January, two thousand and fourteen*

An Act

To expand the program of priority review to encourage treatments for tropical diseases.

*Be it enacted by the Senate and House of Representatives of  
the United States of America in Congress assembled,*

**SECTION 1. SHORT TITLE.**

This Act may be cited as the “Adding Ebola to the FDA Priority Review Voucher Program Act”.

**SEC. 2. PRIORITY REVIEW TO ENCOURAGE TREATMENTS FOR TROPICAL DISEASES.**

Section 524 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n) is amended—

(1) in subsection (a)(3)—

(A) by redesignating subparagraph (Q) as subparagraph (R);

(B) by inserting after subparagraph (P) the following: “(Q) Filoviruses.”; and

(C) in subparagraph (R), as so redesignated, by striking “regulation by” and inserting “order of”; and

(2) in subsection (b)—

(A) in paragraph (2), by adding “There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.” after the period at the end; and

S. 2917—2

(B) in paragraph (4), by striking “365 days” and inserting “90 days”.

*Speaker of the House of Representatives.*

*Vice President of the United States and  
President of the Senate.*